TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomised Controlled Trial of Family Mediated Exercises (FAME) Following Stroke
Brief Summary: The aim of the study is to evaluate the functional recovery in two groups of primary stroke patients presenting with moderate/severe disability over a six month period through the implementation of a randomised controlled trial. The first group or the experimental group will receive routine therapy and additional lower limb exercise therapy in the form of family assisted exercises. The second group or the control group will receive routine therapy with no additional formal input from their family members. A secondary aim of the project is to evaluate the impact of the FAME programme on the person with stroke and the individual (s) assisting in the delivery of exercises.


Options:
A: The primary outcome, caregiver's perceived social support, will be assessed by Medical Outcomes Study Social Support Scale. (Baseline, 3, 6 and 12-months post-stroke)
B: Fugl Meyer (FM) Assessment (Baseline, post intervention and 3 month follow-up)
C: Motor Activity Log - Quality Of Movement (MAL-QOM) and Wolf Motor Function Test - Performance Time (WMFT-PT) (4 weeks (post-treatment) relative to baseline performance)
D: Jette Late Life Functional and Disability Instrument (LLFDI) (3 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode
Brief Summary: The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.


Options:
A: Sick leave data (One year)
B: At-work performance deficits and productivity loss as measured by the Work Limitations Questionnaire (4 months post-randomization); Absenteeism and productivity loss as measured by the Work Limitations Questionnaire Absence Module (4 months post-randomization)
C: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score. (Week 8 to Week 14)
D: Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint] (12 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode
Brief Summary: The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.


Options:
A: Change From Baseline in MADRS Total Score After 8 Weeks of Treatment (Baseline and Week 8)
B: Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment (Baseline and Week 8)
C: Change from randomization to Week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score
D: Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint] (12 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode
Brief Summary: The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.


Options:
A: N/A
B: Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint] (12 weeks)
C: 1. To confirm prospectively the accuracy of an EEG biomarker as a leading indicator of SSRI antidepressant treatment response; (8 weeks)
D: Incidence of depressive disorders in the study population (Measured at baseline, Week 6, and Months 3, 6, 9, 12, and 18)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: The Fagerstrom Test for Nicotine Dependence, expired CO level, and urine cotinine will be used to determine if bupropion SR, when used as an adjunct to antipsychotic medication, is superior to placebo for helping patients with schizophrenia improve their (Expired CO weekly, Fagerstrom baseline and end of study, Urine cotinine baseline, week 2 and week 8); Neuropsychological testing will be used to determine the effects of smoking cessation on patient's attention and memory function. (Beginning and end of study)
B: Primary efficacy and Safety endpoint: (within 12 month from enrollment)
C: Smoking Abstinence - Serum/Urine Measurements (Week 12); Smoking Abstinence - Number of Cigarettes Smoked (Week 12); Smoking Abstinence - Exhaled Carbon Monoxide (Week 12)
D: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) (weeks 8-11 after quit date)
B: Biologically-verified 7-day Point Prevalence Smoking Abstinence (End of treatment (week 6))
C: N/A
D: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: N/A
B: 30 day abstinence (6 months)
C: Smoking Behaviour (56 weeks post participant start date)
D: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) (weeks 8-11 after quit date)
B: 4 week Continuous Quit Rate ( 4 week CQR ) for weeks 9 -12
C: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)
D: Smoking Abstinence (12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: Change in sputum eosinophile-% from >1% to normal or neutrophile-% from >61% to normal, from baseline (week 0) to week 12. (Time frame for primary outcome: 0-12 weeks (total study duration 24 weeks))
B: Percentage of Participants With a Four-Week Continuous Quit Rate (CQR) (Week 9 through Week 12)
C: 7-day point prevalence abstinence measured at 6 months (6 months)
D: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: To Determine the Safety of Varenicline in PLWH Who Smoke (3 months)
B: to assess the continuous abstinence from tobacco smoking at every visit during the last four weeks of treatment through direct inquiry of patients; exhaled carbon monoxide testing; and plasma cotinine measurements
C: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)
D: 4 week continuous quit rate (CQR) at Weeks 9-12 and Weeks 4-7

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)
B: Pocket depth in peridontitis (Change from baseline at 12 months); Per-implant marginal bone loss (Change from baseline at 12 months); Size reduction of oral mucosal diseases (Change from baseline at 12 months)
C: To examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. (8 weeks)
D: Primary Patient Acceptability A: Rate of Patient Wanting Provider to Use QA-DDS (Immediately Post-Consultation up to 1 week); Primary Patient Acceptability B: Rate of Patient Wanting to Use QA-DDS Patient Portal (1-Month Follow-Up); Primary Patient Feasibility A: Rate of Patient Completion of 1-Month Follow-Up Survey (1-Month Follow-Up)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: Self-reported continuous abstinence of smoking and exhaled carbon monoxide levels less than 10 ppm as measured and recorded by the research nurse at weeks 12 and 52. (1 year)
B: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.
C: 7 Day Point Prevalence of Cigarette Abstinence (6-month follow up); 7 Day Point Prevalence of Cigarette Abstinence (Week 8)
D: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: The Fagerstrom Test for Nicotine Dependence, expired CO level, and urine cotinine will be used to determine if bupropion SR, when used as an adjunct to antipsychotic medication, is superior to placebo for helping patients with schizophrenia improve their (Expired CO weekly, Fagerstrom baseline and end of study, Urine cotinine baseline, week 2 and week 8); Neuropsychological testing will be used to determine the effects of smoking cessation on patient's attention and memory function. (Beginning and end of study)
B: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.
C: Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months (6 months)
D: Cotinine-validated 7-day point prevalence tobacco abstinence at 1 year follow-up; Cotinine-validated 7-day point prevalence tobacco abstinence at 3 month follow-up (end of treatment)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Femoral Arterial Access With Ultrasound Trial
Brief Summary: This study is designed to evaluate the routine use of vascular ultrasound as an aid for proper placement of a femoral arterial sheath during cardiac catheterization and peripheral arterial angiography.


Options:
A: elevation of thumb capillary lactate after the procedure (30 days)
B: Superiority of Method of arterial line placement (1 day)
C: Participants With Successful Common Femoral Artery Cannulation, as Determined by Femoral Angiography (Immediately, during procedure.)
D: First Pass Success When Attempting Arterial Catheterization. (Immediate, upon study entry)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Femoral Arterial Access With Ultrasound Trial
Brief Summary: This study is designed to evaluate the routine use of vascular ultrasound as an aid for proper placement of a femoral arterial sheath during cardiac catheterization and peripheral arterial angiography.


Options:
A: Participants With Successful Common Femoral Artery Cannulation, as Determined by Femoral Angiography (Immediately, during procedure.)
B: Time to Successful Radial Arterial Catheterization (up to 5 minutes)
C: success rate of radial artery cathertrization (postoperate 72 hours)
D: Number of Attempts (Immediately during procedure. (up to 30 minutes))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy
Brief Summary: The sleeve gastrectomy that has been utilized as a first-stage bariatric procedure to reduce surgical risk in high-risk patients by induction of weight loss is now gaining popularity as a standalone procedure for the treatment of morbid obesity. It appears to be a technically easier and/or faster laparoscopic procedure than Roux-en-Y gastric bypass. It brings good weight loss results, in some studies even comparable to the RYGB and Biliopancreatic Diversion with Duodenal Switch.

The mechanism of action is assumed to be purely restrictive, but some neurohumoral interaction may exist. Almost no data exist on the influence of the sleeve gastrectomy on the medical and general quality of life or resolution of comorbidities.

The rates of the comorbidities resolution 12 to 24 months after sleeve gastrectomy has been reported in the range that seems to be higher than for the purely restrictive procedures.

Our goal is to to compare the surgical and weight loss outcomes between the two procedures, their influence on resolution of common comorbidities and on quality of life change.

150 eligible candidates will be randomized into two groups, one will undergo Laparoscopic Sleeve Gastrectomy, the other will have Laparoscopic Roux-en-Y Gastric Bypass done. Detailed evaluation and preoperative questionnaires will be used to obtain demographic and medical data, and quality of life will be assessed.

General metabolic and nutritional work up will be done, and will be reassessed at different intervals up to 5 years, in order to compare the short and long term results of the two procedures.


Options:
A: Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT. (1st, 2nd, 3rd, 4th, 5th, 6th, 9th, 12th months)
B: Improvement of co-morbidities (1-year after treatment start)
C: weight loss (5 years)
D: Total Weight Change From Baseline at 12 Weeks in kg (12 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
Brief Summary: The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in the treatment of prostate cancer. The safety of these treatments will also be studied and compared.


Options:
A: Interval before biochemical failure (10 years)
B: Disease specific mortality (Median 15 years follow up)
C: Five-year Disease-free Survival (DFS) Rate (Analysis occurs after all patients have been followed for five years.)
D: Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT) (8.5 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A New Clinical Pathway for Patients With Fractured Neck of Femur - The Orthopedics Operate, the Geriatricians Manage the Medical Work-up
Brief Summary: The intention is to evaluate the effectiveness of a multi-factorial medical treatment of patients with hip fractures in a specially designed unit for elderly hip fracture patients (orthogeriatric unit) as compared to traditional care in an orthopedic unit.


Options:
A: Mobility (1, 4 and 12 months after surgery)
B: Self-rated degree of patient participation in rehabilitation (At discharge from in-patienten rehabilitation, on average 14 days)
C: N/A
D: Montebello Rehabilitation Factor Score (MRFS) (1 day At discharge); Montebello Rehabilitation Factor Score (MRFS) (At 6 months); Montebello Rehabilitation Factor Score (MRFS) (At 1 year); Proportions of patients achieving pre-morbid ambulatory status (1 day At discharge); Proportions of patients achieving pre-morbid ambulatory status (At 6 months); Proportions of patients achieving pre-morbid ambulatory status (At 1 year); Length of stay in hospital (1 day At discharge); Percentage of patients admitted to nursing home (Up to 1 year after discharge)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Treatment of Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone and Laser Photocoagulation: Randomized Clinical Trial With Morphological and Functional Evaluation
Brief Summary: This study compares the use of intravitreous triamcinolone and laser therapy to treat maculopahty in patients with type 2 diabetes mellitus in a short-tem period of 6 months


Options:
A: Change in Central Subfield Retinal Thickness From Baseline Over All Study Visits (Baseline to 3,6,9, and 12 weeks); Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening From Baseline Over All Study Visits (Baseline to 3,6,9, and 12 Weeks)
B: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit (Change from baseline to 12 months)
C: diffuse macular oedema (1, 3 and 6 months)
D: Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years. (Baseline to 2 Years); Median Change in Visual Acuity Baseline to 2 Years (Baseline to 2 Years); Distribution of Change in Visual Acuity Baseline to 2 Years (baseline to 2 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.


Options:
A: Evaluate safety of BHT-3009 alone and when combined with atorvastatin in patients with multiple sclerosis.; Determine dose of BHT-3009 and regimen for phase II testing.
B: number of MRI contrast enhancing lesions (treatment months 6 to 9 compared to baseline)
C: The time to first documented relapse (months 4, 6, 9, 12, and every 3 months from months 18-39)
D: attack number (1 year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.


Options:
A: Time to Major Cardiac Event (Cardiovascular Death, Stroke, Myocardial Infarction, Hospitalization Due to Unstable Angina or Arterial Revascularization) (up to 5 years)
B: attack number (1 year)
C: Major coronary events (sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina pectoris including hospitalization for ischemic episodes,events of angioplasty/ stenting or coronary artery bypass grafting)
D: Assess the effects of rosuvastatin treatment on the change in the mean maximum intima media thickness (IMT) of the 12 vessel segments: the near & far walls of the CCA, the carotid bulb & the ICA

Answer: B